LIBRA-Funded Researchers Present at the World’s Leading Haematology Conference
LIBRA is proud to have supported two researchers from King’s College Hospital to attend the prestigious 67th American Society of Hematology (ASH) Annual Meeting 2025 in Orlando, Florida.
Through travel grants totalling £4,500, LIBRA funded international travel, accommodation and conference registration, enabling both participants to fully engage with one of the most important global events in haematology research.
What is ASH?
The ASH Annual Meeting is the world’s largest and most influential haematology conference, attracting more than 30,000 clinicians, researchers and industry experts from over 100 countries. The conference provides a platform for presenting cutting-edge research, discussing emerging therapies, and exploring the future of diagnosis and treatment for blood cancers and blood disorders.
Presenting research at ASH is highly competitive and reflects the quality and significance of the work being undertaken.
Showcasing LIBRA-Supported Research on the International Stage
During the conference, both researchers attended plenary lectures, oral abstract presentations, educational symposia and poster sessions focused on the latest advances in haematology.
A major highlight was the delivery of an oral presentation showcasing important research into aplastic anaemia. The presentation explored how specific immune cell signatures may help predict treatment response in patients and generated valuable discussion among international researchers and clinicians.
By supporting attendance at ASH 2025, LIBRA helped increase the visibility of King’s College Hospital research on a global stage while enabling researchers to learn from some of the world’s leading experts in blood disorders and transplant medicine.
Learning About the Future of Treatment
The conference gave researchers insight into ground-breaking new therapies and emerging clinical trial data. Topics included innovative stem-cell transplant approaches, advanced immunotherapies and new developments in CAR T-cell therapy.
One particularly exciting area explored was “In Vivo CAR T-Cell Therapy” — an emerging treatment approach that may simplify how CAR T-cell therapies are delivered to patients in the future.
Researchers also reviewed promising developments in treatments for severe aplastic anaemia, including new transplant therapies showing rapid recovery times and encouraging patient outcomes.
Translating Research Into Better Patient Care
In addition to scientific sessions, the researchers attended the ASH industry exhibition, where biotechnology and pharmaceutical companies showcased new therapies, diagnostic tools and late-stage clinical developments.
This exposure helped deepen understanding of how laboratory research is translated into real-world patient treatments and highlighted future opportunities for collaboration and innovation.
Networking events throughout the conference also enabled valuable connections with clinicians, senior investigators and researchers from around the world, creating opportunities for future partnerships and collaborative research.
The Impact of LIBRA’s Support
The knowledge and experience gained at ASH 2025 will directly inform ongoing and future research at King’s College Hospital, particularly in the field of aplastic anaemia and bone marrow failure syndromes.
LIBRA’s support enabled:
- International presentation of LIBRA-supported research
- Access to the latest scientific and clinical developments
- New opportunities for international collaboration
- Greater understanding of emerging therapies and technologies
- Professional development for researchers working at the forefront of haematology
Both researchers expressed their gratitude to LIBRA for making attendance possible and highlighted the significant scientific and professional benefits gained from participating in the conference.
As LIBRA continues to support research, innovation and patient-focused care at King’s College Hospital, opportunities like this play an important role in helping researchers remain connected to the latest global advances in haematology and blood disorder treatment.
Back to all posts